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ABSTRACT
Activation of the Sonic hedgehog signaling pathway, primarily through
mutational inactivation of the PTCH1 gene, is associated with the devel-
opment of basal cell carcinoma (BCC). Gli1, a member of the Gli family
of transcription factors, is expressed in BCC and in transgenic mice
targeted expression of Gli1 in basal keratinocytes leads to BCC develop-
ment. In addition to BCC, previous studies have shown that Gli1 is
expressed in the outer root sheath (ORS) of the hair follicle but is absent
in interfollicular epidermis. In this study, we have characterized the
expression pattern of two protein kinase C (PKC) isoforms expressed in
BCC and hair follicles. We have then used reporter assays to investigate
the effects of these isoforms on Gli1 transcriptional activity. We report
that in BCC sections, PKC but not PKC was weakly expressed in the
epidermis, whereas in the hair follicle, PKC was expressed in the ORS
and PKC in the inner root sheath. In contrast, neither PKC nor PKC
was expressed in BCC tumor islands, although both isoforms were often
expressed in the surrounding stroma. In mammalian 293T cells, coexpres-
sion of constitutively active PKC reduced the activity of Gli1 in a
dose-dependent manner, whereas constitutively active PKC increased
the activity of Gli1, although this required higher expression levels. Reg-
ulation of mutant Gli1 protein localized exclusively to the nucleus was
similar to that of the wild-type protein, indicating that nuclear-cytoplas-
mic shuttling is not a determinant of Gli1 control by either PKC isoform.
Furthermore, PKC regulation of Gli1 did not involve activation of mito-
gen-activated protein kinase signaling. Finally, we show that exogenous
Gli1 does not alter the expression of PKC in human primary keratino-
cytes, suggesting that loss of this isoform in BCC is not via Hedgehog
signaling. As BCCs have been proposed to originate from the ORS, loss of
PKC expression may be relevant to tumor formation; this may, in part,
be because of the predicted increase in Gli1 transcriptional activity.
INTRODUCTION
The Hh5 signaling pathway has been implicated in the regulation of
cell patterning and the cell cycle and plays a critical role in prolifer-
ation, survival, and growth during embryonic development and in the
growth, differentiation, and maintenance of a number of tissues in the
mature organism. Much of what is known about the components and
regulation of Hh signaling was first elucidated by elegant genetic
studies of embryonic segmentation and imaginal disk specification in
Drosophila, and it is now well established that many of the key
elements of the pathway are conserved from invertebrates to verte-
brates. In Drosophila, in the absence of Hh, signal transduction is
repressed by the transmembrane receptor Ptc; this results in the
transcription factor Ci being subject to PKA-dependent proteolytic
cleavage generating a NH2-terminal repressor molecule. Conversely,
the presence of Hh negates Ptc repression such that Ci is not cleaved
and the full-length protein is released to the nucleus where it functions
as a transcriptional activator (reviewed in Refs. 1, 2).
Vertebrates differ from Drosophila in that there are multiple ho-
mologues of a number of components of the pathway. Although this
adds to the complexity, the basic principles of the signaling events
appear to be maintained, and there is evidence that mammalian
homologues can substitute for specific activities when expressed in
Drosophila (3). Three mammalian Hh genes have been identified:
SHh, DHh, and IHh (reviewed in Ref. 4). The mammalian homo-
logues of Ci comprise members of the Gli family of transcription
factors that are characterized by five zinc fingers originally described
in Xenopus transcription factor III A, these are Gli1, Gli2, and Gli3
(5). Several studies have implicated functional redundancy between
Gli proteins and, unlike Ci/Gli2/Gli3, Gli1 does not possess a NH2-
terminal repressor domain (reviewed in Ref. 6).
In adult tissues, inappropriate activation of the Hh pathway has
been linked to the development of a number of tumor types, including
BCC (7). This is primarily because of mutational inactivation of the
PTCH1 tumor suppressor gene, which is proposed to result in in-
creased Gli1 expression (8–11). Also, with regard to medulloblas-
toma, a recent study reported mutations in SUFU resulting in proteins
that are unable to export Gli1 from the nucleus (12).
The mechanisms regulating Gli1 in mammalian cells stem mainly
by analogy to components identified from studies of Ci regulation in
Drosophila. PKA and Su(fu) both negatively control Gli1 activity,
whereas Fu enhances activity. Su(fu) and Fu regulate Gli1 by influ-
encing its subcellular localization and, in the case of the former,
possibly by altering Gli1 transcriptional potential once bound to DNA.
The mechanism of PKA regulation has not been determined, but it
may influence Gli1 binding to DNA (13–17). The importance of
input, however, from other major signal transduction pathways in
regulating Hh signaling and Gli1 activity is not known. Recent evi-
dence has shown that Ci is subject to phosphorylation and regulation
by CK (18). Analysis of the Gli1 coding sequence reveals multiple CK
consensus phosphorylation sites suggesting that it might also be
regulated by CK in mammalian cells. Similarly, Gli1 contains multi-
ple PKC consensus phosphorylation sites, indicating that it may also
be subject to regulation by this enzyme. In human skin, Gli1 is
expressed in the ORS of hair follicles and in BCC but not in interfo-
licular epidermis (19) Moreover, several PKC isoforms are expressed
in human skin (20), and in particular, PKC is reported in the ORS of
murine hair follicles (21). This may be important because the ORS is
thought to be a potential source of BCC.
In this study, we have investigated the pattern of PKC and PKC
in BCC sections and associated hair follicles. We have also investi-
gated the effects of both isoforms on Gli1 reporter activity. We report
that PKC is expressed in the epidermis and ORS of human hair
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follicles but is down-regulated in BCC. Furthermore, we show that
PKC is a potent negative regulator of Gli1 transcriptional activity
and, as it has been proposed that BCC may originate from the ORS
of hair follicles, suggests that loss of PKC is important to BCC
formation.
MATERIALS AND METHODS
Immunohistochemistry. BCC tissue samples were obtained and sections
prepared as described previously (19). Primary mouse monoclonal antibodies
to detect PKC and PKC were obtained commercially (Transduction Labo-
ratories) and used at a concentration of 1:100. For antigen retrieval, sections
were microwave treated under pressure for 4 min at 900 W in preheated citrate
buffer (pH 6.0). Sections were then blocked with horse serum to reduce
nonspecific binding and subsequently incubated for 90 min at room tempera-
ture with primary antibody. Secondary biotinylated antibody (Vectastain Uni-
versal Elite ABC kit; Vector Laboratories, Peterborough, United Kingdom)
was then applied for 30 min at room temperature, followed by avidin biotin
peroxidase complex for 20 min. Visualization was made using 3,3-diamino-
benzidine, then sections were washed in Tris-buffered saline and mounted
using Immunomount (Thermo Shandon).
Cell Culture and Retroviral Production. Mammalian fetal kidney epi-
thelial 293T cells were maintained in DMEM supplemented with 10% FCS.
Human primary keratinocytes were isolated as described previously (22) and
stored in liquid nitrogen before seeding. Primary keratinocytes were cultured
in Defined Serum-free Medium in the presence of growth supplement (Invitro-
gen). Retroviral particles encoding Gli1 and EGFP were produced using the
Phoenix packaging line as described previously (23).
Plasmid Construction. Construction of pI2EA-Gli1 (derived from
pIRES2-EGFP; Clontech) and SIN-Gli1-EGFP has been described previously
(23). To create pI2EA-Gli1mNES, three leucine residues were mutated to
valine (L498V, L501V, and L503V) with pI2EA-Gli1 as template using the
Site-Directed Mutagenesis kit (Stratagene). The luciferase reporter was created
by subcloning 6xGli1 binding sites from the BglII site of pA10CAT6GBS (24)
into the same site of pGL3-Promoter (Promega) creating pGL3P-6GBS.
Transient Transfections and Reporter Analysis. A total of 3  105 293T
cells were seeded in 6-well plates 16–18 h before transfection using Fugene 6
(Roche). For reporter assays, transfections were performed in duplicate with
0.25 g of pI2EA-Gli1/pI2EA-Gli1mNES or control pEGFP-C3 (Clontech),
0.25 g of pGL3P-6GBS, 0.25–1.0 g of pCO2-PKC/-ca (kindly provided
by Peter Parker, London Research Institute, Cancer Research United King-
dom) as indicated, and 0.1 g of pcDNA3.1-Lac Z (Invitrogen)/well; the total
amount of DNA was normalized with empty vector. Six h after transfection,
cells were incubated in fresh standard medium (10% FCS); alternatively, for
analysis of ERK activation, cells were incubated in low serum medium (0.05%
FCS) and in the presence of 1 M U0126 as indicated. Cells were harvested
24–26 h after transfection in 250 l of lysis buffer [0.05 M Tris (pH 7.4), 1 mM
MgCl2, 0.2% IGEPAL CA-360 (Sigma)], vortexed, and incubated on ice for 15
min. Cell lysates were cleared at 13,000 rpm in a tabletop centrifuge for 1 min,
and the supernatant was used for reporter activity and Western blot analysis.
Luciferase and -galactosidase reporter activities were measured with lucifer-
ase substrate (Promega) and chlorophenol red--D-galactopyranoside (Roche
Biochemicals), respectively, using a microtiter plate reader (Victor Multilabel
Counter; Wallac, Turku, Finland).
Western Blotting and Antibodies. Protein samples were separated on
10% SDS-polyacrylamide gels and transferred to nitrocellulose membrane
(Amersham Pharmacia) according to standard protocols. Protein loading was
normalized to Lac z activity or total protein levels. Primary antibodies that
were obtained commercially include Gli1 (Santa Cruz Biotechnology), phos-
pho-p38 MAPK (NEB), phospho-ERK (NEB), PKC (Transduction Labora-
tories), and phospho-PKC/ (NEB). The phospho-serine 657 antibody
(PKC) was a gift from Peter Parker (London Research Institute). Secondary
horseradish peroxidase-linked antibodies were obtained commercially (Dako),
and immunodetection was performed with enhanced chemiluminescence 
reagent (Amersham Pharmacia).
RESULTS
PKC Isoforms Are Differentially Expressed in BCC, Interfol-
licular Epidermal Cells, and Hair Follicle ORS Keratinocytes. To
determine whether PKC may be involved in BCC development, we
first investigated the expression of PKC and PKC in BCCs by
immunohistochemistry using isoform-specific antibodies. These iso-
forms are known to be expressed in human primary keratinocytes and
Fig. 1. Immunohistochemical analysis of PKC expression in BCC sections. A–C, PKC was detected in the mesenchyme surrounding tumor islands (A) and in the ORS of the hair
follicle (B and C) but not within tumor islands (A and B). D–F, PKC was detected in stromal cells and capillaries surrounding tumor islands (D and E) and in the inner root sheath
of the hair follicle (F) but not within tumor islands (D and E). Note that images A and D, B and E, and C and F are of adjacent sections and that images B, C, E, and F are from the
same section.
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represent classical and novel PKC isoforms, respectively (20). Seven
different BCC sections were analyzed, including two with hair folli-
cles, which allowed for direct comparison between different structures
of the skin. PKC immunoreactivity was detected in basal keratino-
cytes of the interfollicular epidermis (data not shown) and strongly in
the ORS of hair follicles (Fig. 1, B and C). In contrast, PKC was only
weakly expressed or absent in BCC tumor islands (Fig. 1, A and B).
PKC did, however, show heterogeneous expression in the stroma
surrounding BCCs (Fig. 1, A and B), and expression was also ob-
served in the connective tissue sheath surrounding the hair follicle
(data not shown). In contrast to strong basal PKC expression in the
ORS of hair follicles, PKC expression was mainly restricted to the
inner root sheath of the hair follicle, and only occasional, weak
immunoreactivity was detected in the ORS (Fig. 1F). Similar to
PKC, PKC expression was predominantly negative in BCC tumor
islands, whereas heterogeneous expression was observed in the stroma
(Fig. 1, D and E).
Gli1 Is Differentially Regulated by PKC Isoforms. In view of
the biological differences between Gli1 expressing BCC and ORS
keratinocytes and the differences in the expression of the PKC iso-
forms between BCC and ORS keratinocytes, we investigated the
effects of PKC and PKC on Gli1 transcriptional activity. This was
performed using PKC-ca (constitutively active) mutants and a lucif-
erase reporter construct containing 6xGli1 binding sites in mammalian
293T cells. PKC-ca decreased Gli1 activity by over 60% in a
dose-dependent manner (Fig. 2A), whereas PKC-ca increased Gli1
activity in a dose-dependent manner, resulting in a 2-fold stimulation
of reporter activity at the highest concentration of plasmid used (Fig.
2B). Additional stimulation of Gli1 was achieved using higher con-
centrations of PKC-ca plasmid (data not shown). Neither PKC iso-
form altered reporter activity when coexpressed with EGFP (data not
shown).
To determine whether changes in Gli1 activity were because of
changes in Gli1 protein level, we carried out Western blot analysis of
reporter lysates. Fig. 2C shows that at the highest concentration of
plasmid used (1 g), PKC stimulated an increase in Gli1 protein
levels when compared with controls, whereas PKC had no effect.
The paradoxical stimulation of Gli1 expression but down-regulation
of reporter activity indicates that PKC-ca reduction of Gli1 activity
would have been more marked had reporter activity been normalized
for Gli1 protein.
PKC Regulation of Gli1 Transcriptional Activity Is not De-
pendent upon Nuclear-cytoplasmic Shuttling. Recent studies have
shown that Gli1 is subject to nuclear-cytoplasmic shuttling, which is
controlled by nuclear export and nuclear localization motifs (Ref. 15
and unpublished data). Although the subcellular localization of Gli1 is
dependent upon cell type, its expression pattern is predominantly
cytoplasmic and punctate in 293T cells as shown by an EGFP fusion
protein (Fig. 3A). Mutation of residues in the nuclear export motif
produces a mutant protein that is localized exclusively to the nucleus,
Gli1mNES, as shown by an EGFP fusion protein (Fig. 3A). Therefore,
we sought to determine whether the subcellular location of Gli1
determined its regulation by PKC by analyzing the regulation of
Gli1mNES (nonfusion protein). Coexpression of PKC-ca resulted in
a decrease in Gli1mNES activity in a similar manner to that of native
Gli1, and coexpression of PKC-ca resulted in up-regulation of
Gli1mNES activity (Fig. 3B). We also confirmed that PKC-ca did
not alter the subcellular location of nuclear Gli1 by coexpression with
EGFP-Gli1mNES (data not shown). Combined with the fact that
PKC regulation is similar between Gli1 and Gli1mNES, this suggests
that nuclear-cytoplasmic shuttling is not a determinant of Gli1 regu-
lation by either isoform and indicates that PKC may influence signal-
ing pathways that regulate Gli1 in the nucleus.
PKC Regulation of Gli1 Is not Dependent upon MAPK Acti-
vation. The downstream effects of PKC are mediated through several
different pathways, including activation of Raf-MAP kinase kinase-
ERK signaling (25, 26). Therefore, we investigated if PKC regulation
of Gli1 is mediated via this classical signaling pathway. As PKC-ERK
(p42/44 MAPK) activation may be cell specific, we initially deter-
mined if either PKC isoform activates ERK in 293T cells. Expression
of PKC-ca, but not PKC-ca, induced activation of ERK as shown
by the level of phospho-ERK with Western blot analysis (Fig. 4A).
However, as a recent study has shown that Gli1 induces ERK activa-
tion in C3H10T1/2 cells (27), we assessed if Gli1 also induces ERK
activation in 293T cells because this could affect our interpretation of
PKC-Gli1 regulation via ERK. We observed no activation of ERK
by Gli1 indicating that Gli1 activation of Ras-ERK signaling may be
cell specific (Fig. 4A).
To determine if PKC regulation of Gli1 occurs through ERK
activation, cells were incubated in the presence of the drug U0126, a
specific inhibitor of its upstream activator MAP kinase kinase. The
presence of U0126 had no effect on Gli1 activity or protein stability,
indicating that PKC-Gli1 regulation occurs through an ERK-inde-
pendent mechanism (Fig. 4, B and C). Western blot analysis con-
firmed that U0126 (1 M) inhibited the activation of ERK by PKC
(Fig. 4C). The effects of PKC signaling can also be mediated by p38
MAPK (28–31). However, Western blot analysis revealed that neither
PKC nor PKC influenced p38 activity as determined by the level of
phospho-p38 MAPK, thus excluding this kinase from PKC regulation
of Gli1 in 293T cells (data not shown). Our data therefore shows
Fig. 2. Effect of PKC isoforms on Gli1 transcriptional activity and protein stability in
mammalian 293T cells. A, coexpression of Gli1 with increasing amounts of PKC-ca
induced a dose-dependent decrease of Gli1 transcriptional activity. B, coexpression of
Gli1 with increasing amounts of PKC-ca induced a dose-dependent increase of Gli1
transcriptional activity. C, Western blot analysis of reporter lysates revealed that coex-
pression of PKC-ca induced an increase of Gli1 protein, whereas PKC-ca had no effect
when compared with expression of Gli1 alone. Error bars represent SE of three inde-
pendent experiments performed in duplicate.
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that PKC regulation of Gli1 does not involve p38 MAPK or ERK
signaling.
Gli1 Does not Regulate the Expression or Activity of PKC in
Human Primary Keratinocytes. The origin of BCC is uncertain, but
proposed sites of tumor initiation include the basal layer of the
epidermis and the ORS of the hair follicle. PKC is expressed in both
these regions but is absent in adjacent tumor islands, indicating that its
loss of expression may be required for tumor formation or growth. As
Gli1 is expressed in the ORS and tumor islands and is fundamental to
BCC formation, we investigated if Gli1 affects the expression of
PKC in primary human keratinocytes using retroviral transduction.
We have previously shown that retrovirally expressed Gli1 induces
endogenous PTCH and Gli2 expression in keratinocytes, indicating
protein functionality (23). By Western blot analysis, we found that the
total level of PKC was not altered in Gli1 cells compared with
control EGFP cells (Fig. 5). Furthermore, Gli1 did not alter the
activation of PKC as shown with antibodies specific for two of the
three phosphorylation sites (threonine 638 and serine 657) that regu-
late PKC activity (Fig. 5; Ref. 32, 33). This suggests that loss of
PKC in BCC is not dependent upon Hh signaling.
DISCUSSION
Gli1 is expressed extensively in the ORS of human hair follicles but
not in interfollicular epidermis (19). The mechanisms regulating Gli1
activity in mammalian cells is still poorly understood with much of
the focus on components identified from studies of Ci regulation in
Drosophila. Although it is well recognized that there are tissue spe-
cific differences in the downstream consequences of activation of SHh
signaling, the basis for these differences is unclear. In this article, we
now present data showing that the transcriptional activity of Gli1 is
subject to regulation by PKC and suggest that this may play an
important role in tumor development. We have investigated the pat-
terns of expression of PKC and PKC in interfollicular epidermis,
hair follicles, and BCC. We found that PKC is extensively expressed
in the ORS of human hair follicles and weakly in basal epidermal
keratinocytes, and this is consistent with the expression pattern in
murine epidermis (21). A previous study reported that PKC is not
expressed in BCC, and we have confirmed this observation (34).
Fig. 3. Nuclear-cytoplasmic shuttling is not a determinant of
Gli1 regulation by PKC. A, expression of an EGFP-Gli1 fusion
protein demonstrates that Gli1 is predominantly cytoplasmic and
punctate in 293T cells (i); mutation of residues that control
nuclear export produces a mutant protein (EGFP-Gli1mNES) that
is localized exclusively to the nucleus (ii). B, coexpression of
PKC-ca reduced Gli1mNES (nonfusion protein) transcriptional
activity, whereas PKC-ca increased Gli1mNES activity. Error
bars represent SE of three independent experiments performed in
duplicate.
Fig. 4. PKC regulation of Gli1 does not involve MAPK signaling. A, PKC-ca, but not
PKC-ca or Gli1, induced phosphorylation and activation of ERK in 293T cells as shown
by Western blot analysis. B and C, the presence of the drug U0126 did not inhibit the
decrease in Gli1 transcriptional activity or increase in protein stability induced by
PKC-ca; inhibition of ERK activation by U0126 was determined by Western blot
analysis of reporter lysates. Error bars represent SE of three independent experiments
performed in duplicate.
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The combined observations that Gli1 is expressed in the ORS of
hair follicles and in BCC but not interfollicular epidermis and, more-
over, our observation that PKC is also expressed in the ORS of the
hair follicle but down-regulated in BCC led us to speculate that PKC
might regulate Gli1 activity. We found that coexpression of PKC
reduced the transcriptional activity of Gli1 by 60%. Furthermore,
we also observed that PKC increased the level of Gli1 protein and,
as such, if the data were normalized for protein content the reduction
in Gli1 activity would be even greater. Interestingly, in a previous
study we demonstrated by immunostaining that Gli1 is more strongly
expressed in the ORS than BCC tumor islands despite an abundance
of Gli1 transcript in the tumors (19). Combined with the results of the
present study, this suggests that PKC regulates Gli1 protein levels in
vivo and that the reduction of Gli1 in BCC compared with the ORS
is possibly attributable to the concomitant reduction in PKC
expression.
The data from our reporter assays reveal that Gli1 activity is not
completely suppressed by PKC (Fig. 2C). However, it is likely that
the transformation to a neoplastic phenotype may only require a slight
increase in Gli1 activity to disrupt normal cell homeostasis. Recent
evidence has shown that the function of tumor suppressor genes may
depend on the level of protein expressed. Haploinsufficiency has been
proposed as the genetic basis for neoplasia in PTCH heterozygous
mice, and a recent study has demonstrated that after loss of heterozy-
gosity, a 50% reduction in expression of the remaining APC allele
may be sufficient to induce colorectal neoplasia (35, 36). By analogy,
an increase in the activity of oncogenic transcription factors, either by
increased expression or by down-regulation of negative regulatory
elements, may be sufficient to promote tumorigenesis.
In BCC, the absence of PKC in tumor islands may result in Gli1
being transcriptionally more potent, and this may subsequently pro-
mote BCC formation and/or growth. Dahmane et al. (8) hypothesized
that Gli1 expression in BCC could not be accounted for solely by
expression of SHh or activation of the pathway via mutation of
PTCH1. They subsequently proposed that any mutation leading to the
induction of SHh signaling would result in Gli1 expression and BCC
formation. Alternatively, because SHh signaling is active during hair
follicle growth, they also suggested that neoplastic transformation of
these cells may induce BCC formation (8). The latter hypothesis
correlates with the evidence presented here from which we propose
that loss of PKC expression in the ORS may promote tumor forma-
tion. This is also consistent with several immunostaining studies that
suggest that BCC originates from the ORS (37–40). As well as the
ORS, PKC is expressed in the interfollicular epidermis and BCC
may occur because of ectopic expression of Gli1 in cells of the basal
layer. As PKC is down-regulated in the majority of BCC (Ref. 34
and this study), this indicates that whatever the derivation of the tumor
or its mode of Gli1 expression, the activity of Gli1 will be enhanced
in the absence of PKC. It would be interesting to determine the
expression profile of PKC in Gli1-transgenic mice, which develop
BCC in the absence of PTCH1 mutations, and because the profile of
PKC is similar in normal murine epidermis to that presented here
(21, 41).
Gli1 is subject to regulation by nuclear import and export sequences
(Ref. 15 and unpublished data), and the expression pattern of Gli1 is
predominantly cytoplasmic and punctate in 293T cells as it forms part
of a protein complex attached to the cytoskeleton. One potential
mechanism for PKC control of Gli1 could be via the regulation of
proteins such as Fu or Su(fu) that control the subcellular localization
and activity of Gli1 (13–16). We have shown that the regulation of a
mutant Gli1 protein localized exclusively to the nucleus is similar to
that of the wild-type protein, indicating that PKC regulation of Gli1
is not dependent upon changes in subcellular location; this suggests
that PKC regulation of Gli1 activity is more direct.
PKC signaling is often mediated through downstream activation of
either ERK (p42/44 MAPK) or p38 MAPK. However, using specific
drug inhibitors, we have discounted the possibility that PKC (and
PKC) regulates Gli1 through MAPK activation. As well as control-
ling its subcellular localization, Su(fu) also reduces the activity of
Gli1 bound to DNA, and it is possible that the negative control of Gli1
by PKA may be through reduced DNA binding (14, 15). Analysis of
the Gli1 coding sequence reveals multiple PKC consensus phospho-
rylation sites throughout the protein, including the zinc fingers, indi-
cating that Gli1 may be a direct target of PKC. We found no
evidence that Gli1 is phosphorylated upon coexpression with
PKC-ca as determined by Western blot analysis (Fig. 2C), but this
technique may not be sensitive enough to detect phosphorylated Gli1,
and more sensitive assays such as two-dimensional gel electrophoresis
or in vitro labeling may be required. Alternatively, Gli1 could be
indirectly regulated by PKC, and this may or may not involve Gli1
phosphorylation.
Several studies have shown that SHh signaling is crucial for the
morphogenesis of skin appendages such as the hair follicle and feather
bud (reviewed in Ref. 42), but only little is known about the potential
cooperation between SHh and PKC signaling in these structures. The
induction of feather bud dermal condensations by SHh-tumor growth
factor-2 signaling is associated with the suppression of PKC expres-
sion (43, 44), and exposure of hair follicles to phorbol esthers such as
phorbol 12-myristate 13-acetate/12-O-tetradecanoylphorbol-13-ace-
tate potently inhibits follicle growth (45–47). Interestingly, the activ-
ity of Gli1 is also reduced by phorbol 12-myristate 13-acetate (un-
published data). These studies suggest reciprocal negative regulation
between SHh and PKC signaling. How PKC expression is down-
regulated in BCC remains to be determined. We found no evidence
that Gli1 regulates PKC expression or activity in human primary
keratinocytes, and this suggests that other factors regulate PKC in
the skin and its appendages.
Finally, in addition to PKC, we have also investigated the expres-
sion pattern of PKC and its effect on Gli1 reporter activity. In
contrast to PKC, PKC stimulated Gli1 reporter activity. However,
as we did not detect PKC expression in BCC tumor islands, it is most
likely that PKC up-regulation of Gli1 activity does not play an
important role in BCC tumor formation per se. Despite this, PKC
was expressed in stromal cells surrounding tumor islands, and we
cannot exclude the possibility that PKC mediates epithelial-mesen-
chymal cross-talk and may influence tumor development in this way.
In summary, we have determined that PKC is normally expressed
in the basal layer of the epidermis, as well as the ORS of the hair
follicle. Both of these compartments have been proposed as the sites
Fig. 5. Gli1 does not regulate the expression or activity of PKC in keratinocytes.
Western blot analysis revealed that the expression of PKC was not altered in primary
cells expressing Gli1 via retroviral transduction (i) nor was its activity altered as shown
with antibodies specific for residues that control activation (ii and iii) when compared with
control EGFP cells. Confirmation of Gli1 expression was also performed by Western
blotting (iv).
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of tumor formation, and although our data are unable as yet to shed
light on which of these may be the origin of tumors, we have shown
that PKC negatively regulates Gli1 activity. This is important be-
cause PKC is down-regulated in BCC, whereas Gli1 is expressed in
BCC. We therefore propose that loss of PKC expression in BCC
may play a key role in tumor development.
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